Jury orders Gilead to pay Merck $2.5bn in patent case

December 16, 2016

A US jury has ordered pharmaceutical giant Gilead Sciences to pay $2.5 billion to competitor Merck in a patent infringement case involving a drug used to treat hepatitis C, the two companies said.

A in Delaware on Thursday sided with Merck subsidiary Idenix, which claimed that Gilead's blockbuster sofosbuvir drug and its derivatives, sold under the labels Solvadi et Harvoni, violated one of its patents.

"The patent at issue in this case facilitated significant advances in the treatment of patients with HCV infection and was appropriately granted," Merck said in a statement.

"Achieving these advancements required many years of research and significant investment by our subsidiary and its partners," it added.

Gilead announced plans to appeal the ruling, and said the decision would not affect its ability to supply the drug to US patients.

Sofosbuvir came under the Gilead portfolio in 2011, when the biotech company acquired Pharmasset, which held the drug's patent.

Hepatitis C, a blood-borne viral disease, affects 130 to 150 million people globally and can result in or cancer.

According to the World Health Organization, it is responsible for 700,000 deaths yearly.

Explore further: Jury: Gilead owes Merck $200M in damages over drug patents (Update)

Related Stories

Jury: Gilead owes Merck $200M in damages over drug patents (Update)

March 25, 2016
The federal jury in a patent trial has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages for infringing on patents for hepatitis C drugs.

Jury finds for Merck in hepatitis drug fight with Gilead

March 22, 2016
A federal jury in California has ruled in favor of drugmaker Merck & Co. in a high-stakes lawsuit against rival Gilead Sciences Inc. over patents for lucrative new drugs that rapidly cure hepatitis C.

Charity scores small win in Hep C drug battle

October 5, 2016
A medical charity scored a small victory Wednesday in its bid to break a US pharma giant's hold on an eye-wateringly expensive Hepatitis C drug when a European body partially revoked the firm's patent.

Gilead wins India patent for blockbuster Hepatitis drug

May 10, 2016
India has granted a patent to US pharmaceutical giant Gilead for a blockbuster Hepatitis C drug, in a U-turn activists said could potentially stop affordable copies reaching millions of people in other countries.

French charity attacks Gilead patent for hepatitis drug

February 10, 2015
French charity Medecins du Monde (MdM) on Tuesday said it was contesting a European patent awarded to a hepatitis drug made by US firm Gilead Sciences, arguing the treatment was too costly.

US group seeks to block Gilead drug patent in India

November 24, 2013
A US-based patient rights group said Saturday it has sought to block a bid by California-based Gilead Sciences to obtain an Indian patent for a potentially blockbuster drug to treat hepatitis C.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.